ADMA Biologics: Bollinger Bands Narrowing, KDJ Death Cross on 15-minute chart.

ADMA Biologics's 15-minute chart has recently exhibited Bollinger Bands Narrowing, accompanied by a KDJ Death Cross as of October 7th, 2025, at 10:30. This indicates that the magnitude of stock price fluctuations is diminishing, while the momentum of the stock price is trending downward and has the potential to continue to decrease.

Adma Biologics (ADMA) has recently shown signs of a potential downward trend in its stock price, according to technical indicators. As of October 7th, 2025, at 10:30, the 15-minute chart exhibited Bollinger Bands Narrowing, accompanied by a KDJ Death Cross. This combination suggests that the magnitude of stock price fluctuations is diminishing, while the momentum of the stock price is trending downward, indicating a potential continuation of this trend.

Bollinger Bands Narrowing typically signals a period of consolidation or reduced volatility in the stock's price. Meanwhile, the KDJ Death Cross is a bearish signal that indicates a potential reversal in the stock's price momentum. Together, these indicators suggest a cautious outlook for ADMA Biologics' stock performance.

In the broader market context, ADMA Biologics closed at $15.05 in the latest trading session, marking a +2.66% move from the prior day. This gain was more significant than the S&P 500's daily gain of 0.34%. While the stock has dropped by 14.77% in the past month, it has outperformed the Medical sector's gain of 1.97% and the S&P 500's gain of 3.54% Why Adma Biologics (ADMA) Outpaced the Stock Market Today^[1].

Analysts predict ADMA Biologics to post an EPS of $0.16 for the current quarter, indicating a 6.67% growth compared to the same quarter last year. The consensus estimate predicts revenue to be $130.1 million, indicating an 8.56% increase compared to the previous year. For the full year, the Zacks Consensus Estimates project earnings of $0.57 per share and a revenue of $506.7 million, demonstrating changes of +16.33% and +18.82%, respectively, from the preceding year Why Adma Biologics (ADMA) Outpaced the Stock Market Today^[1].

Despite the positive earnings projections, the stock is currently trading at a Forward P/E ratio of 25.72, which is a premium compared to its industry average Forward P/E of 18.92. The Medical - Biomedical and Genetics industry, which includes ADMA Biologics, has a Zacks Industry Rank of 80, placing it in the top 33% of all industries Why Adma Biologics (ADMA) Outpaced the Stock Market Today^[1].

Investors should monitor ADMA Biologics closely, as recent modifications to analyst estimates can provide insights into the company's business trends and profit potential. The Zacks Rank, a proprietary model that assesses changes in analyst estimates, currently rates ADMA Biologics as a #3 (Hold) Why Adma Biologics (ADMA) Outpaced the Stock Market Today^[1].